StartUp Health NOW Podcast

The episode is densely packed with specific, actionable frameworks for health tech founders navigating CMS and Medicare payment models. Abe Sutton clearly articulates outcome-aligned payment structures, the three-legged stool of regulatory success (market access, data, reimbursement), and the critical distinction between exploiting loopholes versus building sustainable models. However, the rapid-fire format dilutes insight density in the second half as questions become increasingly specific to individual companies, reducing generalizability for the broader audience.

“If we could improve people's health outcomes on these key metrics for the amount we're paying, it is a good deal for CMS”

“Think through the incentive of why the thing exists...is the business model you are building something that aligns with our actual goal, or is it exploiting a loophole that we inadvertently created?”

Sutton offers fresh, counterintuitive perspectives on policy thinking - particularly the distinction between loophole-exploitation versus sustainable models, and the strategic advice to frame proposals as solving systemic problems rather than company-specific pilots. The concept of 'stroke of the pen risk' and the three-legged-stool framework are relatively novel framing devices for the healthcare startup ecosystem. However, the core payload (outcome-based payment, value-based care) reflects established CMS direction and has been discussed in health policy circles for years.

“'Why would I use a shot on goal on something small?' is more intellectually interesting than standard policy talk”

“The distinction between deflationary versus exploitative business models”

Abe Sutton is exceptionally well-positioned: he has operated as a startup founder (demonstrating real business acumen), now serves as a senior leader at CMS responsible for designing and testing new payment models at scale, and directly controls the policy and funding mechanisms that determine whether health tech companies succeed or fail. This is rare operator-plus-policy expertise. The rapid-fire format features multiple founders, but Sutton is the primary value driver, and his vantage point is nearly unmatched for a health tech audience.

“Abe Sutton from CMS...leads the team responsible for designing, testing, and scaling new payment models that determine how the federal government pays for care”

“He leads the innovation center with ability to deploy new payment models”

The episode includes concrete examples (AI doctor for free under Stark/anti-kickback protections, GUIDE dementia model results expected 2027, Alzheimer's device therapy at $10-12k vs. $200-300k lifetime cost for monoclonal antibodies) and specific program references (MAHA Elevate, TEFCAOnly). However, many claims lack supporting numbers: Sutton mentions '1,600 letters of intent' for one program but doesn't quantify uptake, outcomes, or savings. The rapid-fire section asks good specificity questions but receives vague answers in some cases ('close to 1,600 letters of intent'). Data density is moderate, not exceptional.

“a typical Alzheimer's patients with an eighteen thousand to twenty thousand dollar a year monoclonal antibodies...costs the system two, three hundred thousand dollars, or they can get a device...that cost ten thousand, twelve thousand dollars”

“We've got close to 1,600 letters of intent”

The host does ask solid clarifying questions and the rapid-fire format generates specific founder queries that Sutton must address concretely. However, the host rarely pushes back or probe deeper when Sutton gives partial answers. For example, when Sutton advises companies to frame proposals as 'big' solutions rather than pilots, no one asks *how* to authentically reframe a genuinely niche solution without overselling. The conversational tone is deferential rather than adversarial - soft questioning dominates. The best moments come from founder questions, not host facilitation.

“My key question to you would be, what is the way that your technology is applied in a deflationary manner, and is there a way you are comfortable taking on the risk in that transition?”

“Are you looking at the strength of the prior clinical outcomes, ability to generate new cost and utilization methods or, or uptake in Medicare Part B population?”